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TLC-densitometryAbstract Counterfeiting of pharmaceutical products is a global problem. Upon using quality-
ensuring methods of international pharmacopoeias, additional impurities and the low content of
the active pharmaceutical ingredients were detected. In this paper, two chromatographic HPLC
and TLC-densitometric methods were proposed as fast and reliable methods for detection and
quantitation of counterfeit Plavix tablets. These tablets were chemically counterfeited by aspirin,
its degradate salicylic acid and metronidazole which were separated, besides the active ingredient
clopidogrel bisulfate, by the proposed methods. Also, counterfeit was in packaging, strips and tab-
lets’ color and these could be seen by visual inspection compared to original drug. The proposed
methods can easily differentiate genuine from counterfeited tablets without need of prior separa-
tion. The proposed methods were validated according to ICH guidelines and applied to eleven
batches, also were compared statistically with the reported one.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Counterfeit drugs have a long history all over the world and it
is estimated by economy as worthy trade. The problem of
counterfeiting is huge and it can be life threaten.1 The term
counterfeit medical product describes a product with a false
representation of its identity and for source. This is appliedto the product, its container or packaging or labeling informa-
tion. Counterfeiting can be applied by both branded and
generic products.2
The world health organization (WHO) website reports
many recent events on drugs counterfeiting either natural or
synthetic including all kinds of medicine.3 FDA ofﬁce of crim-
inal investigation published some cases which indicated the
growth and enhancing of counterfeit drug problem.4 Anticoag-
ulant, ﬁbrinolytic and antiplatelet drugs are an important cat-
egory of medicine. They are used during cardiac and brain
surgery and for prevention of cardiac and cerebro disorders.5
Clopidogrel bisulfate (CLP) (methyl (S)-2-chlorophenyl
(4,5,6,7-tetrahydrothieno-[3,2-c]pyridine-5-yl) acetate bisul-
fate) is an ADP antagonist. Aspirin (2-acetoxy benzoic acid)
is cyclooxygenase inhibitor. The two drugs are major
antithrombogenic agents that are widely used for the treatment
92 M.E. ElTantawy et al.and prevention of cerebro and cardiovascular conditions such
as stroke.6–8 These two antiplatelet agents are used combined
to produce enhanced therapeutic effect in many pharmaceuti-
cal formulations.
A survey of previous analytical methods of CLP, it was
analyzed in human plasma by HPLC9–13 and GC.14 Clopido-
grel was assayed alone15,16 and in presence of inactive
metabolite SR26334 and chiral impurity in human plasma in
dosage forms by HPLC17 and TLC.18 A stability-indicating
HPLC19,20 and TLC21,22 methods were established for
determination of CLP. Different methods were used for the
analysis of aspirin either alone, combined with other drugs
or combined with CLP using HPLC,23–27 HPTLC28 and
spectrophotometry.29,30
This research is considering detection and analysis of
counterfeit Plavix tablets by new validated HPLC and
TLC-densitometric methods. There were many complaints
from the patients in Egypt that Plavix tablets were not
effective and from Sanoﬁ-Aventis Company that this product
was counterfeited. Concerning counterfeiting of CLP, many
published cases were reported abroad1; however, no researches
were done to study this problem in Egypt. Different eleven
samples of this product were collected from the Sanoﬁ-
Aventis, after taking their permission, and the Egyptian
market as an example of developing countries.
2. Experimental
2.1. Instruments
HPLC Agilent 1200 series was equipped with a model series
ED62962752 LC quaternary pump, Rheodyne injector Lot
ID 7725 with a 20 lL loop and UV detector DE71360313
(Germany). The instrument was connected to an IBM compat-
ible PC and HP disk jet printer.
TLC 20 · 20 cm aluminum sheets are precoated with silica
gel F254, 0.25 mm thickness, Merck (Germany). The plates
were activated at 105 C for 15 min before use. The samples
were applied to the plate using a 25 lL Hamilton Analytical
Syringe. CAMAG dual wavelength ﬂying spot densitometer
was used with video display and high-speed, high-quality, par-
allel-head printer plotter (Switzerland). The instrument was
connected to an IBM compatible PC and HP disk jet printer.
The experimental conditions of the measurements were; k:
225 nm, the measuring mode: absorbance, slit dimensions:
4 · 0.3 mm, scanning speed: 20 mm s1, data resolution:
100 lm/step, optimize optical system for maximum: light and
band width: 20 mm.
pH meter HANAA 8417 (Portugal).
Mass spectrometer ISQ single quadripole Thermo Scientiﬁc
was working by electronic ionization positive mode; 70 elec-
tron volt (Japan) and using X Caliber library software.
Fourier transform infrared spectrophotometer (FTIR),
Prestige-21 was connected to IBM compatible computer with
IR solution software.
A double beam UV–Visible spectrophotometer (Shimadzu,
Japan) model UV-1601 PC with quartz cell of 1 cm pathlength,
was connected to IBM compatible computer. The software was
UVPC personal spectroscopy software version 3.7. The spec-
tral bandwidth was 2 nm and wavelength-scanning speed
2800 nm min1.2.2. Materials and chemicals
2.2.1. Drug standard
- Clopidogrel bisulfate was kindly supplied by Sanoﬁ Aven-
tis, Cairo Egypt; its purity was 99.30%± 0.84 according
to the reported HPLC method.27
- Aspirin was kindly supplied by Boehringer Ingelheim,
Cairo Egypt; its purity was 100.25%± 0.46 according to
the reported HPLC method.27
- Salicylic acid was kindly supplied by Adwic, Cairo Egypt;
its purity was 100.99%± 0.76.
- Metronidazole was kindly supplied by Sanoﬁ Aventis,
Cairo Egypt; its purity was 100.05%± 0.43.
2.2.2. Pharmaceutical dosage forms (drug product)
Plavix tablets were labeled to contain 75 mg CLP, manufac-
tured by Sanoﬁ Aventis, Cairo, Egypt. Eleven samples of Pla-
vix tablets were collected from inspection department,
NODCAR and Sanoﬁ Aventis Company; batch No.: 0A078,
1525, 1922, 1A514, 0A156, 2147, 1476, 2114, 2424, 1565 and
2A753 (genuine).
2.2.3. Chemicals
All chemicals used were of analytical grade, and the solvents
were of HPLC and spectroscopic grade.
Disodium hydrogen phosphate dihydrate, (Riedel-de
Ha¨en), acetonitrile of HPLC grade (S.D. Fine-Chem. Lim-
ited), methanol, phosphoric acid, petroleum ether 60–80 C,
ethyl acetate, acetone, and acetic acid (Adwic) were used.
The water for HPLC was prepared by double glass distillation
and ﬁltration through a 0.45 lm membrane ﬁlter.
2.3. Chromatographic conditions
2.3.1. For HPLC method
Separation and quantitation were made on column ACE
C18-AR, 250 · 4.6 mm, 5 lm particle size. The detector was
set at 250 nm. The mobile phase was prepared by mixing a
mixture of 0.1 M disodium hydrogen phosphate dihydrate
pH 2.2 ± 0.2 adjusted with phosphoric acid and acetonitrile
(50:50, v/v). The mobile phase was ﬁltered using 0.45 lm dis-
posable ﬁlter (Millipore, Milford, MA) and degassed by ultra-
sonic vibrations prior to use. The samples were also ﬁltered
using 0.45 lm disposable ﬁlters. The ﬂow rate of the mobile
phase was 1.0 mL min1. A volume of 20 lL of each sample
solution was injected.
2.3.2. For TLC-densitometric method
The TLC plates were developed in a mixture of petroleum
ether–ethyl acetate–acetone–acetic acid (70:20:5:5, by volume)
as a developing system. The chosen scan mode was the zigzag
mode and the wavelength of the scanning was chosen to be
225 nm for all the drugs. For detection and quantiﬁcation, 2
to 20 lL of the standard solutions within the quantiﬁcation
range was applied as separate compact spots 20 mm apart
and 20 mm from the bottom of the plate using a 25 lL
Hamilton Analytical Syringe. The plate was developed up to
14 cm in the usual ascending way. The chromatographic tank
(b)
(a)
ASP
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Figure 1 Chromatograms of (a) mixture of aspirin and salicylic acid (75.0 lg mL1 of each) and clopidogrel bisulfate (30.0 lg mL1) by
the proposed HPLC method. (b) Mixture of aspirin, salicylic acid and clopidogrel bisulfate (3.75 lg/spot of each) by the proposed TLC-
densitometric method.
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elution the plate was air dried and scanned for the cited com-
ponents at 225 nm as under the described instrumental
parameters.
2.4. Standard solutions
Stock standard solutions of CLP, ASP and SAL
(750.0 lg mL1) in methanol were prepared for the proposed
HPLC and TLC-densitometric methods.
2.5. Methods
2.5.1. Construction of calibration curve
2.5.1.1. For HPLC method. Aliquots of CLP, ASP and SAL
stock standard solution (750.0 lg mL1 in methanol) equiva-
lent to 75.0–1500.0 lg were accurately transferred into a seriesTable 1 System suitability parameters of the proposed HPLC meth
Parameter Obtained value
ASP SAL
Resolution (Rs) 4.91
Selectivity (a) 1.17
Tailing factor (T) 0.87 0.83
Capacity factor (K0) 1.12 1.47
Number of theoretical plates (N) 14097 15935
HETP Height equivalent to
theoretical plate (cm/plate)
1.8 · 103 1.6 · 103
Retention time min ± 0.2 3.6 4.2of 10-mL volumetric ﬂasks, the volume was completed to the
mark with a mixture of water and acetonitrile (50:50, v/v).
Triplicate 20 lL injections were made for each concentration
and chromatographed under the conditions described above.
The peak area of each concentration was plotted against the
corresponding concentration to obtain the calibration curves
then the regression equations were computed.
2.5.1.2. For TLC-densitometric method. Separate volumes in
lL from each CLP, ASP and SAL stock standard solutions
(750.0 lg mL1 in methanol) were accurately applied to the
TLC plates to get the range of 1.5–15.0 lg/spot for CLP and
1.5–12.0 lg/spot for ASP and SAL, respectively. Triplicate
applications were made for each solution, the plates were chro-
matographed as mentioned above and the peak areas were
measured. The calibration curves were constructed and the
regression equations were computed.od.
Reference value
CLP
21.23 >1.5
1.95 >1
0.95 1
3.76 1–10
18400 Increase with eﬃciency of separation
1.4 · 103 The smaller the value the
higher the column eﬃciency
8.1
Table 2 Characteristic parameters of clopidogrel bisulfate, aspirin and salicylic acid by the two proposed methods.
Characteristic parameter HPLC method TLC-densitometric method
CLP ASP SAL CLP ASP SAL
Range 7.5–150.0 lg mL1 7.5–150.0 lg mL1 7.5–150.0 lg mL1 1.5–15.0 lg/spot 1.5–12.0 lg/spot 1.5–12.0 lg/spot
Linearity
Slope 6.3808 4.6657 10.9220 1182.50 1775.60 1236.10
Intercept 2.6672 1.6707 3.6984 258.34 2897.20 3223.10
Correlation coeﬃcient (r) 0.9997 0.9999 0.9999 0.9995 0.9995 0.9990
SE of the slope a 0.0872 0.0363 0.0457 20.38 31.27 32.20
CL of the slope b 6.1034–6.6583 4.5504–4.7811 10.7761–11.0670 1117.62–1247.32 1676.14–1875.16 1133.62–1338.58
SE of the intercept 8.0135 3.3323 4.2020 187.67 249.29 256.73
CL of the intercept 22.8352–28.1697 8.9342–12.2756 17.0712–9.6743 338.90–855.60 2103.83–3690.56 2406.06–4040.12
Accuracy (mean ± RSD) 99.77 ± 1.23 99.56 ± 1.12 99.27 ± 1.30 99.25 ± 1.05 100.90 ± 0.34 100.03 ± 1.08
Precision (% RSD)
Repeatability c 0.27 0.43 0.50 1.07 1.07 1.21
Intermediate precisiond 0.46 0.60 0.75 1.16 1.70 1.46
Robustnesse 99.95 ± 0.99 99.98 ± 1.09 100.60 ± 0.59 99.57 ± 1.21 99.06 ± 0.68 99.61 ± 1.28
LODf 2.07 lg mL1 2.12 lg mL1 1.36 lg mL1 0.47 lg/spot 0.47 lg/spot 0.48 lg/spot
LOQf 6.27 lg mL1 6.43 lg mL1 4.13 lg mL1 1.43 lg/spot 1.45 lg/spot 1.46 lg/spot
a Standard error.
b Conﬁdence limit.
c The intraday (n= 9), average of three different concentrations repeated three times within day.
d The interday (n= 9), average of three different concentrations repeated three times in three successive days.
e Average in the change of pH (±0.2), ﬂow rate (±0.1 min) and ratio of mobile phase (±2%) in the HPLC method and average in the change of each developing system component (±4%) of the
TLC-densitometric method.
f Limit of detection and quantitation are determined via calculations, LOD= (SD of the response/slope) · 3.3; LOQ= (SD of the response/slope) · 10.
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Table 3 Analysis of genuine clopidogrel bisulfate by the proposed methods and application of the standard addition technique.
Formulation The proposed HPLC method
Plavix tablets Labeled to contain 75 mg,
batch No. 2A753.
Assay* Taken (lg mL1) Added (lg mL1) Found* (lg mL1) Recovery %
99.33 ± 0.42 112.50 7.50 7.37 98.27
30.00 30.39 101.30
37.50 36.75 98.00
Mean ± RSD 99.19 ± 1.85
Formulation The proposed TLC-densitometric method
Plavix tablets Labeled to contain 75 mg,
batch No. 2A753.
Assay* Taken (lg/spot) Added (lg/spot) Found* (lg/spot) Recovery %
99.33 ± 0.55 11.25 1.50 1.47 98.00
3.00 3.04 101.33
3.75 3.68 98.13
Mean ± RSD 99.15 ± 1.90
* Average of 3 determinations.
Table 4 Visual inspection of Plavix tablets.
Original drug Counterfeit drug
1. Packaging as carton box (security label)
2. Strips
3. Color of tablets
Chromatographic determination of clopidogrel bisulfate 95
(a)
(b)
CLP CLP
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Figure 2 Chromatograms of (a) Plavix tablets, batch No. 2114 by the proposed HPLC and TLC-densitometric methods. (b) Plavix
tablets, batch No. 1476 by the proposed HPLC and TLC-densitometric methods.
Table 5 The average results of the Plavix batches assay by the proposed HPLC and TLC-densitometric methods.
Batch No. Clopidogrel bisulfate (%) Aspirin (mg/tablet) Salicylic acid (mg/tablet) Metronidazole (mg/tablet)
2A753 99
2114 77 – – 10
1476 – – – 12
0A078 22 – – –
1525 42 – – –
1922 129 – – –
1A514 127 – – –
0A156 150 – – –
2147 – 46.7 13 –
96 M.E. ElTantawy et al.2.5.2. Pharmaceutical formulation preparation
A total of ten tablets were weighed and ﬁnely powdered. Into
a 100-mL volumetric ﬂask, a portion of the powdered tablets
equivalent to 75.0 mg of CLP was accurately weighed and
dissolved in about 70 mL of methanol with the aid of ultra-
sound for 15 min. The volume was completed with the same
solvent to give ﬁnal concentration of 750.0 lg mL1. The
sample solution was then ﬁltered using 0.45 lm ﬁlter
(Millipore, Milford, MA). The general procedures for the
proposed methods described under construction of calibra-
tion curves were followed. The peak area was used for
determination of this drug in the sample using the regression
equation.2.6. Identiﬁcation of the adulterated tablets
The tablets were ground, dissolved in methanol by the aid of
ultrasonic waves for 15 min and ﬁltered. The ﬁltrate was evapo-
rated to residue for identiﬁcation by mass and IR spectrometry.
3. Results and discussion
Five categories in counterfeit drugs are deﬁned by WHO31: (1)
Mislabeled counterfeit, (2) Counterfeit containing less active
pharmaceutical ingredients (API), (3) Counterfeits with wrong
API, (4) Counterfeits with no API, (5) API in the correct
amount but with fake packaging and labeling. In contrast to
Figure 3 Mass spectra of (a) the unknown compound found in Plavix tablets, batch No. 2114 and 1476. (b) The standard mass
spectrum of metronidazole found in mass spectrometer library.
Chromatographic determination of clopidogrel bisulfate 97these categories which are mostly occurring in developing
countries, the substandard drugs are often found in developing
countries. The proposed methods were used for determination
of CLP alone or with ASP and its degradation product SAL,
also it could detect and quantify the counterfeit drugs.
3.1. HPLC method
Several trials were carried out to obtain a good resolution
between the cited components. These trials involved the use
of different mobile phases with different ratios, different pHs
and ﬂow rates. The best resolution with sharp and symmetric
peaks was obtained upon using the chromatographic condi-
tions described under 2.3.1. The pH of the mobile phase was
critical for the separation of CLP. By increasing the pH, the
retention time of CLP was delayed. The speciﬁcity of
the HPLC method is illustrated in Fig. 1 where separation of
the cited components is noticed. The retention time for CLP,
ASP and SAL was 8.1, 3.6 and 4.2 ± 0.2 min, respectively.
System suitability parameters of the proposed HPLC method
were calculated showing good resolution, selectivity and
symmetrical peaks according to the USP32 (Table 1).3.2. TLC-densitometric method
Experimental conditions such as developing system, scan mode
and wavelength of the detection were optimized to provide
accurate, precise and reproducible results for determination
of the cited components. The optimum developing system
was described under 2.3.1. Robustness was done during the
method development and recovery % was calculated as in
Table 2. The Rf was found to be ±0.03. Acetone and acetic
acid were added to the developing system to fasten the separa-
tion and prevent tailing, respectively. The chosen scan mode
was the zigzag mode and the wavelength of the scanning was
chosen to be 225 nm for all the drugs. The separated spots
of the cited drugs were scanned separately on the same plate
at the selected wavelength. The greatest differences between
Rf values of the components; the Rf values for CLP, ASP
and SAL were 0.78, 0.54 and 0.65 ± 0.03, respectively, as
shown in Fig. 1.
Characteristic parameters for regression equations of the
proposed HPLC and TLC-densitometric methods and correla-
tion coefﬁcient obtained by least squares treatment of the
results are given in Table 2.
Figure 4 IR spectrum of (a) the unknown compound found in Plavix tablets, batch No. 2114 and 1476. (b) Standard Metronidazole.
98 M.E. ElTantawy et al.Method validation was performed according to the ICH
guidelines33 for the two proposed methods. Table 2 shows
results of accuracy, repeatability and intermediate precision
of the methods.
The proposed methods were applied to the determination
of CLP in pharmaceutical formulation Plavix tablets, genuine
batch No. 2A753. Five replicate determinations were made.
Satisfactory results were obtained for CLP and were in agree-
ment with the labeled claims, Table 3. The validity of the pro-
posed methods was assessed by applying the standard addition
technique to original batches that contain CLP. Accurate
results were shown in Table 3 and there is no interference from
excipients.
The proposed methods were used for determination and
quantitation of the counterfeit Plavix tablets by visual inspec-
tion and chemical composition.- Visual inspection as shown in Table 4 (photographs of
samples); (1) Security label: Sanoﬁ-Aventis developed
technologies against counterfeiting through packaging
protection. Programs intended for making them difﬁcult
to copy and easier to authentication (Tamper-proof
systems – visual and hidden authentication system). (2)
Strips: counterfeit samples showed different colors, shapes
and kind of foils used in strips. (3) Color of tablets: coun-
terfeit samples show different colors compared to the origi-
nal one.
- Chemical composition in batches 0A078, 1525, 1922,
1A514, 0A156, 2147, 1476, 2114 showed counterfeit of
CLP as shown in Table 5. By HPLC and TLC-densitomet-
ric methods, it was found that some batches contain no
active constituent (CLP) and others contain ASP and
SAL only and unknown substance.
Figure 6 UV spectrum of clopidogrel bisulfate (150.0 lg mL1) (____), aspirin (37.5 lg mL1) (. . .. . ...) and salicylic acid (3.75 lg mL1)
(- - - -) in methanol.
Figure 5 UV spectrum of the unknown compound (18.0 lg mL1) (____) found in Plavix tablets batch No. 1476 and the spectrum of
metronidazole standard (12.5 lg mL1) (- - - -) in methanol.
Chromatographic determination of clopidogrel bisulfate 99 Batch No. 2147 did not contain clopidogrel but was adul-
terated by aspirin and salicylic acid of amount 46.7 mg
and 13 mg/tablet, respectively. This was conﬁrmed by com-
parison with standards of aspirin and salicylic acid giving
the same retention time and Rf values by the proposed
HPLC and TLC-densitometric methods, (Fig. 1).
 The batch No. 2424 and 1565 were counterfeit in
packaging.
 The batch No. 2114 contained 77% CLP and unknown
substance and batch No. 1476 contained unknown sub-
stance only. The unknown substance was showing retention
time of 2.7 ± 0.2 min and Rf 0.1 ± 0.03 by the proposed
HPLC and TLC-densitometric methods as shown in
Fig. 2 and Table 5.
The analysis of the unknown substance was done by mass
spectrometry with library, IR spectrometry and UV spectro-
photometry as shown in Figs. 3–6. The mass spectrum of theunknown compound matched with the standard metronida-
zole in the library of the mass spectrometer showing m/z 172
as molecular weight. The IR spectrum of the unknown com-
pound showed the OH-stretch at 3225 cm1, CH-stretch at
2852 cm1, CH aromatic-stretch at 1472 cm1. The UV spec-
tra of the unknown compound were identical with the metro-
nidazole standard. The unknown substance was predicted to
be metronidazole and conﬁrmed by injection of standard met-
ronidazole using the proposed methods.
Fig. 7 shows the chromatograms of six batches of Plavix
tablets by the proposed methods. Batch No. 0A078, 1525,
1922, 1A514, 0A156 and 2147.
Statistical comparison of the results of CLP analysis
obtained by the proposed methods and the reported HPLC
one27 was also done using student’s t-test and the F-ratio at
95% conﬁdence level (Table 6), it was clear that there was
no signiﬁcant difference between the proposed methods with
regard to accuracy and precision.
Batch
0A078. 
Batch
1525.
Batch
1922.
Batch
1A514.
Batch
0A156.
Batch
2147.
CLP
CLP
CLP
CLP
CLP CLP
CLP
CLP
CLPCLP
ASP SALSAL
ASP
Figure 7 Chromatograms of Plavix tablets by the proposed HPLC and TLC-densitometric methods. CLP (clopidogrel bisulfate), ASP
(aspirin) and SAL (salicylic acid).
Table 6 Statistical comparison between the proposed and reported methods.
Parameter Clopidogrel bisulfate
HPLC method TLC-densitometric method Reported methodc
Mean ± RSD a 99.77 ± 1.23 100.38 ± 0.73 99.30 ± 0.84
SD 1.23 0.73 0.83
Variance 1.51 0.53 0.69
n 5 5 5
Student’s t-test (2.306)b 0.709 2.188
F-value (6.39)b 2.19 1.30
a Average of ﬁve determinations.
b Values of theoretical t and F values at P= 0.05.
c Reported HPLC method27 on C18 column Phenomenex, (250 · 4.6 mm) Luna 5l. The mobile phase was acetonitrile: 50 mM potassium
dihydrogen phosphate buffer: methanol, solution pH adjusted to 3, in the ratio 50:30:20, v/v. The ﬂow rate was 1.5 ml/min and detection
wavelength 240 nm.
100 M.E. ElTantawy et al.
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The proposed methods are fast, reliable, precise and accurate
for quantitative analysis of CLP and its application in quality
control laboratories. This work allows the distinction between
very bad counterfeit, very good imitation and other samples
from genuine samples. Chemical counterfeits of CLP are done
by aspirin, salicylic acid and metronidazole which were sepa-
rated, besides the active ingredient, by the proposed methods.
Counterfeit in packaging, strips and tablets’ color can be seen
by visual inspection comparing with the original drug.
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